Cite
HARVARD Citation
Atkins, M. et al. (2023). Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. Journal of clinical oncology. 41 (2), pp. 186-197. [Online].